###begin article-title 0
Urea-Mediated Cross-Presentation of Soluble Epstein-Barr Virus BZLF1 Protein
###end article-title 0
###begin p 1
Conceived and designed the experiments: SB HW LD. Performed the experiments: SB RG TB JL BW. Analyzed the data: SB RG. Contributed reagents/materials/analysis tools: PL WJ. Wrote the paper: SB JL LD.
###end p 1
###begin p 2
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 983 991 983 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 300 318 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 320 323 <span type="species:ncbi:10376">EBV</span>
###xml 558 561 <span type="species:ncbi:10376">EBV</span>
Soluble extracellular proteins usually do not enter the endogenous human leukocyte antigen (HLA) I-dependent presentation pathway of antigen-presenting cells, strictly impeding their applicability for the re-stimulation of protein-specific CD8+ cytotoxic T lymphocytes (CTL). Here we present for the Epstein-Barr virus (EBV) BZLF1 a novel strategy that facilitates protein translocation into antigen-presenting cells by its solubilisation in high molar urea and subsequent pulsing of cells in presence of low molar urea. Stimulation of PBMC from HLA-matched EBV-seropositive individuals with urea-treated BZLF1 but not untreated BZLF1 induces an efficient reactivation of BZLF1-specific CTL. Urea-treated BZLF1 (uBZLF1) enters antigen-presenting cells in a temperature-dependent manner by clathrin-mediated endocytosis and is processed by the proteasome into peptides that are bound to nascent HLA I molecules. Dendritic cells and monocytes but also B cells can cross-present uBZLF1 in vitro. The strategy described here has potential for use in the development of improved technologies for the monitoring of protein-specific CTL.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 949 950 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 644 662 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 977 980 <span type="species:ncbi:10376">EBV</span>
CD8+ T lymphocytes (CTL) play a key role in the immunological control of persistent intracellular pathogens and tumors. Thus, the development of improved technologies for the monitoring and expansion of protein-specific CTL represents a major challenge in clinical immunology. CTL specifically target infected cells through the recognition of peptides displayed by surface exposed HLA class I molecules. In most cell types, HLA class I-associated peptides are generally derived from cytosolic proteins. In contrast, delivery of soluble exogenous proteins to the endogenous HLA class I processing pathway is scarce. Here we exemplified with the Epstein-Barr virus immediate early protein BZLF1 a novel and simple urea-based strategy to deliver soluble proteins to the class I processing pathway of antigen-presenting cells by cross-presentation. We showed that urea formulated BZLF1 but not urea-free BZLF1 reveals a strong capacity to reactivate CD8+ T cells in blood cells of EBV-positive donors. Accordingly, dendritic cells, monocytes, but also B cells are able to cross-present BZLF1-derived epitopes to CTL. This technology could improve the development of T cell diagnostics for microbial diseases and may facilitate a novel strategy for the expansion of protein-specific CTL for therapeutic application.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 674 677 674 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Rock1">[1]</xref>
###xml 678 681 678 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Trombetta1">[3]</xref>
###xml 1159 1160 1159 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1505 1508 1505 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-KovacsovicsBankowski1">[4]</xref>
###xml 1509 1512 1509 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Sigal1">[6]</xref>
###xml 1534 1537 1534 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Heit1">[7]</xref>
###xml 1557 1560 1557 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Limmer1">[8]</xref>
###xml 1577 1580 1577 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Tvinnereim1">[9]</xref>
###xml 1666 1670 1666 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Rock2">[10]</xref>
###xml 1671 1675 1671 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Rodriguez1">[11]</xref>
###xml 1773 1777 1773 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Rock2">[10]</xref>
###xml 1778 1782 1778 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Castellino1">[12]</xref>
###xml 1783 1787 1783 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Gromme1">[13]</xref>
Cytotoxic CD8+ T lymphocytes (CTL) play a key role in the immunological control of persistent intracellular pathogens and tumors. CTL specifically target infected cells through the recognition of peptides, which are displayed by surface exposed HLA class I molecules. In most cell types, HLA class I-associated peptides are generally derived from intracellularly synthesized proteins. For the processing in the endogenous antigen presentation pathway, peptides are generated by the proteasome and translocated by the transporter associated with antigen processing (TAP) to the lumen of the endoplasmic reticulum, where they are trimmed and loaded onto HLA class I molecules [1]-[3]. The resulting complexes of mature HLA class I molecules and peptides are transported through the secretory pathway for display on the cell surface, where they can interact with CTL. In contrast, exogenous soluble antigens are typically internalized by antigen-presenting cells (APC) via the endosomal route, proteolytically fragmented in acidic endosomal compartments and loaded onto HLA class II molecules to produce a mature complex, which is capable of interacting with CD4+ T helper (Th) cells. However, APC have the capacity to internalize pathogens as well as infected and abnormal cells from their environment and direct them to the endogenous HLA class I processing machinery by a process termed cross-presentation. Efficient cross-presentation of exogenous antigens is achieved by dendritic cells and macrophages [4]-[6], but also by B cells [7], endothelial cells [8] and neutrophils [9] via various routes for antigen delivery from endosomes and phagosomes to the cytosol [10],[11] or by direct processing of captured antigens in intracellular vesicles or at the plasma membrane [10],[12],[13]. Yet, evidence for the stimulation of CTL by soluble exogenous proteins is scarce.
###end p 6
###begin p 7
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Lindner1">[14]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Ribas1">[15]</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Schnorrer1">[16]</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Dhodapkar1">[17]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Schnurr1">[18]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Stittelaar1">[19]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Javid1">[20]</xref>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Frankel1">[21]</xref>
The development of protein delivery systems for APC is one of the main challenges in T cell diagnostics, vaccinology and cellular therapy. Current strategies include intracellular synthesis of foreign antigens by infection of APC with microbial live vectors or transfection with expression vectors and RNA [14],[15]. In addition, coupling of antigens to micro beads [16], antibodies [17],[18], lipids [19], heat shock proteins [20] and arginine-rich protein transduction domains (PTD) [21] confers delivery to the HLA class I processing machinery. However, a variety of practical and theoretical concerns, such as restrictions in the translocation of individual antigens, the lack of biological inertness of the transfer vectors and/or difficulties with the preparation and use of more complex experimental systems preclude versatile applications in diagnostics, therapy and prevention of infectious diseases and tumors.
###end p 7
###begin p 8
Here we demonstrate a substantial improvement of HLA class I-dependent antigen presentation to CTL by urea treatment, which facilitates an efficient antigen translocation to the endogenous cytosolic processing pathway.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 23 26 <span type="species:ncbi:10376">EBV</span>
Urea-adjuvated soluble EBV BZLF1 specifically stimulates CTL
###end title 10
###begin p 11
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Mellman1">[22]</xref>
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Trombetta2">[23]</xref>
Soluble extracellular proteins are almost exclusively processed by the exogenous pathway for presentation on HLA class II molecules, thus strictly limiting their capacity to activate specific CTL responses [22],[23]. Here we investigated, whether the denaturation of protein in a high molar urea solution and its subsequent incubation with APC in the presence of low concentrations of urea mediates an improved protein delivery into the endogenous antigen processing and presentation pathway.
###end p 11
###begin p 12
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Bogedain1">[24]</xref>
###xml 746 752 738 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g001">Fig. 1</xref>
###xml 1118 1119 1110 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1213 1214 1201 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1264 1271 1252 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000198.s001">Fig. S1</xref>
###xml 1593 1594 1581 1582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1604 1611 1592 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000198.s002">Fig. S2</xref>
###xml 1794 1800 1782 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g002">Fig. 2</xref>
###xml 1899 1906 1887 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000198.s003">Fig. S3</xref>
###xml 2034 2041 2022 2029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000198.s004">Fig. S4</xref>
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
###xml 304 307 <span type="species:ncbi:10376">EBV</span>
###xml 1342 1345 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 2120 2123 <span type="species:ncbi:10376">EBV</span>
As a model antigen we used the EBV BZLF1 protein, since it has been previously described to harbor an immunodominant B8-restricted CTL epitope termed RAK [24], thus offering a suitable read-out system for the detection of BZLF-specific CTL reponses. Heparinized whole blood obtained from HLA B8-positive EBV-positive individuals was stimulated with either 10 microg/ml urea-adjuvated BZLF1 (uBZLF1) or dialyzed urea-free BZLF1, while the synthetic RAK peptide and a 0.04 M urea solution served as positive and negative controls, respectively. Exposure of blood cells with uBZLF1 induced the reactivation of substantial numbers of CTL as shown by intracellular IFN-gamma staining, which was not seen in cells stimulated with BZLF1 or 0.04 M urea (Fig. 1), even after prolongued incubation times (data not shown). In addition, the frequencies and ratios of specifically reactivated CTL upon stimulation with uBZLF1 and the RAK peptide differed significantly in blood samples of individual donors. The removal of urea from uBZLF1 by extensive dialysis resulted in an almost complete loss of its capacity to stimulated CD8+ T cells. Furthermore, we observed only low or undetectable numbers of IFN-gamma producing CD4+ Th cells in response to stimulation with uBZLF1 (Fig. S1). Comparable results were achieved using recombinant cytomegalovirus (CMV) pp65 protein (Miltenyi Biotec). Urea-formulated pp65 (upp65) but not urea-free dialyzed pp65 induced significant reactivation of pp65-specific CTL, whereas removal of urea did not significantly influence the capacity of (u)pp65 to restimulate CD4+ T cells (Fig. S2). Dose titration studies with urea revealed no significant cytotoxic effects at concentrations of 0.04 M urea present in uBZLF1-stimulated peripheral blood mononuclear cells (PBMC) (Fig. 2). Beyond that, the applied urea solution did neither induce the secretion of cytokines from PBMC (Fig. S3) nor activate immature dendritic cells for the upregulation of costimulatory (CD80, CD83 and CD86) and MHC class-II molecules (Fig. S4). These data indicate that urea formulation mediates an efficient transfer of EBV BZLF1 into the endogenous HLA class I presentation pathway.
###end p 12
###begin title 13
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Urea-treated BZLF1 (uBZLF1) but not untreated BZLF1 restimulates specific CD8+ cytotoxic T lymphocytes.
###end title 13
###begin p 14
###xml 305 306 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 309 310 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 317 318 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 321 322 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
Whole blood from an EBV-seropositive, HLA B8-positive donor was stimulated with either 10 microg/ml of BZLF1 or uBZLF1 and as controls with 10 microg/ml of RAK peptide and 0.04 M urea. Cells were incubated at 37 Cdegrees for 7 h with 10 microg/ml BFA added for the last 4 h. Shown is the percentage of CD3+CD8+ or CD3+CD4+ cells expressing IFN-gamma from a representative stimulation of eight independent experiments using a total of 4 different donors. Plots show log fluorescence intensity.
###end p 14
###begin title 15
Residual urea in uBZLF1 pulsed cell cultures reveals no significant cytotoxic effect on lymphocytes.
###end title 15
###begin p 16
PBMC of two healthy adult individuals, indicated by the light and dark grey bars, were incubated with increasing concentrations of urea. Cell viability was determined after 20 h by propidium iodide (PI) staining.
###end p 16
###begin title 17
Transfer of uBZLF1 to the HLA class I presentation pathway is not mediated by a PTD-like domain within the C-terminal region of BZLF1
###end title 17
###begin p 18
###xml 352 359 352 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g003">Fig. 3A</xref>
###xml 484 496 484 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 527 534 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 536 543 532 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g003">Fig. 3B</xref>
###xml 667 679 659 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 893 905 877 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 996 1003 976 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g003">Fig. 3C</xref>
###xml 527 534 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 584 587 <span type="species:ncbi:10376">EBV</span>
###xml 797 800 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
During the last decade short arginine-rich protein-transduction domains (PTD) have been described to mediate polypeptide translocation across cell membranes. Sequence alignments revealed the presence of an arginine-rich domain within the C-terminal region of BZLF1 exhibiting similarities to a known PTD domain of the Antennapedia (Antp) homeoprotein (Fig. 3A). To examine the role of this PTD-like domain in the translocation of uBZLF1 into APC, we expressed a deletion mutant (BZLF1Delta176-189), lacking the putative PTD in E. coli (Fig. 3B). We stimulated PBMC of HLA B8-positive EBV-seropositive healthy donors with either 10 microg/ml uBZLF1 or truncated uBZLF1Delta176-189 and determined the number of specifically restimulated, IFN-gamma secreting T cells by ELISpot. PBMC stimulated with HIV Gag-derived peptide E10F served as negative control. In these experiments, uBZLF1 and uBZLF1Delta176-189 showed no significant differences in their capacity to reactivate BZLF1-specific T cells (Fig. 3C), indicating that the predicted PTD within BZLF1 plays no significant role in urea-mediated protein translocation into the endogenous processing pathway of APC.
###end p 18
###begin title 19
Deletion of a C-terminal arginine-rich domain within BZLF1 with homology to PTD does not abrogate the capacity of uBZLF1 to activate specific T cells.
###end title 19
###begin p 20
###xml 93 100 89 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">176&#8211;189</sub>
###xml 119 126 115 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 175 196 171 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">materials and methods</xref>
###xml 236 243 228 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">176&#8211;189</sub>
###xml 385 392 369 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">176&#8211;189</sub>
###xml 119 126 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 300 303 <span type="species:ncbi:10376">EBV</span>
###xml 400 403 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) A truncated BZLF1 protein, engineered by deletion of the arginine-rich domain (BZLF1Delta176-189) was expressed in E. coli, purified and treated with urea as described in materials and methods. (B) The purity of BZLF1 and BZLF1Delta176-189 was assessed by Coomassie staining. (C) PBMC of healthy EBV-seropositive donors were stimulated for 20 h with 10 microg/ml uBZLF1, BZLF1Delta176-189 or the HIV control peptide E10F and the frequencies of IFN-gamma producing cells were assayed by ELISpot. The data show mean spot forming cell (SFC) values+/-standard deviation (s.d.) of 5 replicate stimulations and are a representative of results performed with PBMC of 3 different individuals.
###end p 20
###begin title 21
uBZLF1 enters APC via a cross-presentation pathway
###end title 21
###begin p 22
###xml 994 1001 956 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g004">Fig. 4A</xref>
We used specific inhibitors of the HLA class I processing and presentation pathway to evaluate the molecular mechanisms underlying the urea-mediated uptake, processing and presentation of BZLF1. In order to study the energy dependency of uBZLF1 uptake into APC, PBMC were pre-incubated for 45 min at 4degreesC or 37degreesC and subsequently pulsed at the same temperature with uBZLF1 or the RAK peptide for an additional two hours. After removal of excessive antigen by washing, cells were incubated for an additional 20 h at 37degreesC and the numbers of IFN-gamma producing T cells were determined by ELISpot. Pre-incubation and pulsing of cells with uBZLF1 at 4degreesC resulted in significantly reduced numbers of IFN-gamma producing T cells compared to PBMC pulsed at 37degreesC, indicating a temperature sensitive and thus energy-dependent uptake of uBZLF1. In contrast, the efficiency of CTL reactivation by the RAK peptide was independent of the pre-incubation and pulsing temperature (Fig. 4A).
###end p 22
###begin title 23
Uptake of uBZLF1 occurs in temperature-dependent manner by clathrin-mediated endocytosis.
###end title 23
###begin p 24
(A) This uptake and cross-presentation of uBZLF1-derived epitopes is inhibited at 4degreesC. PBMC were pulsed for 2 h at 4degreesC or 37degreesC with uBZLF1 or RAK peptide. The number of BZLF1-specific lymphocytes was determined by ELISpot. (B) Cross-presentation of uBZLF1 is blocked by sucrose, an inhibitor of clathrin-mediated endocytosis. Donor PBMC were stimulated with either uBZLF1 or the RAK peptide in presence of the indicated concentrations sucrose and the frequency of IFN-gamma secreting cells was analyzed. Sucrose did not exhibit cytotoxic effects on PBMC at the used concentrations, as shown by PI-staining. All ELISpot data show mean SFC values+s.d. of 5 replicate stimulations and are representative of results performed with PBMC of 2 different individuals.
###end p 24
###begin p 25
###xml 383 390 383 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g004">Fig. 4B</xref>
To further analyze the internalization process of uBZLF1, PBMC were pre-treated and stimulated for 20 h with uBZLF1 or RAK peptide in the presence of sucrose, an inhibitor of clathrin-mediated endocytosis. Specific activation of CTL by uBZLF1-pulsed PBMC was substantially abrogated in a dose dependent manner by sucrose, while CTL activation by the RAK peptide was hardly affected (Fig. 4B). Herein, sucrose did not exhibit cytotoxic effects on PBMC at the used concentrations, as shown by propidium iodide (PI) staining. These results indicate an uptake of uBZLF1 by clathrin-mediated endocytosis.
###end p 25
###begin p 26
###xml 239 240 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Paludan1">[25]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Kalish1">[26]</xref>
###xml 748 755 744 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g005">Fig. 5A</xref>
###xml 432 435 <span type="species:ncbi:10376">EBV</span>
To examine the role of proteolytic processes within endolysosomal compartments in the processing of uBZLF1 for epitope presentation on HLA class I molecules, we pre-treated PBMC for 45 min with two inhibitors of lysosomal acidification, NH4Cl or chloroquine [25],[26], and subsequently stimulated cells for an additional 20 h with uBZLF1 or RAK peptide in presence of the indicated inhibitors. Treatment of PBMC of HLA B8-positive, EBV-seropositive donors with both inhibitors did not significantly influence the capacity of uBZLF1 and the RAK peptide to specifically stimulate T cells for IFN-gamma production, strongly indicating that lysosomal protein degradation plays no significant role in the generation of HLA class I presentable epitopes (Fig. 5A).
###end p 26
###begin title 27
uBZLF1 is processed by a cross-presentation pathway.
###end title 27
###begin p 28
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 822 823 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cross-presentation of uBZLF1 is not influenced by (A) inhibition of endolysosomal acidification using chloroquine or NH4Cl, (B) but is significantly abrogated in presence of the proteosomal inhibitors epoxomycine and lactacystine. The ELISpot data show mean SFC values+s.d. of 5 replicate stimulations and are representative of results performed with PBMC of 3 different individuals. None of the applied drugs exhibited cytotoxic effects on PBMC at the used concentrations, as shown by PI-staining. (C) BFA strongly inhibits cross-presentation of uBZLF1. Whole blood was stimulated with uBZLF, RAK-peptide or, as control, 0.04 M urea in presence or absence of BFA. IFN-gamma production was analyzed by intracellular staining using flow cytometry. The data show the number of specifically reactivated IFN-gamma positive CD8+ T cells and are representative of experiments performed with 3 different donors.
###end p 28
###begin p 29
###xml 421 428 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g005">Fig. 5B</xref>
###xml 83 86 <span type="species:ncbi:10376">EBV</span>
To analyze the involvement of the proteasome in the degradation of uBZLF1, PBMC of EBV-seropositive donors were cultured and stimulated with uBZLF1 or the RAK peptide for 20 h in the presence of epoxomicine or lactacystine, both inhibitors of proteasomal proteases. These substances caused substantial impairment of uBZLF1-mediated CTL activation, with lactacystine showing a stronger inhibitory effect than epoxomycine (Fig. 5B). In contrast, both compounds showed no significant inhibition of T cell reactivation upon stimulation with the RAK peptide. These results demonstrate that processing of uBZLF1 requires proteolytic activities from the proteasome complex.
###end p 29
###begin p 30
###xml 721 728 717 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g005">Fig. 5C</xref>
###xml 305 308 <span type="species:ncbi:10376">EBV</span>
Subsequently, we determined the sensitivity of HLA class I presentation of uBZLF1-derived epitopes to brefeldin A (BFA), an inhibitor of anterograde endoplasmic reticulum-golgi transport and hence an inhibitor of the endogenous HLA class I presentation pathway. Therefore, we pre-incubated whole blood of EBV-seropositive, HLA B8-positive donors with BFA for 45 min prior to stimulation with uBZLF1, the RAK control peptide or a 0.04 M urea solution for additional 7 h and analyzed the frequency of specifically reactivated CTL by intracellular IFN-gamma staining. BFA significantly abrogated uBZLF1-induced reactivation of specific T cells, whereas activation of CTL by the RAK peptide was not significantly influenced (Fig. 5C), implicating that newly synthesized HLA class I molecules are required for an efficient presentation of uBZLF1-derived peptides. Taken together, these observations strongly suggest that the capacity of uBZLF1 to restimulate specific CTL relies on the uptake and processing of the antigen via a cross-presentation pathway.
###end p 30
###begin title 31
Dendritic cells, monocytes and B cells are capable of cross-presenting uBZLF1
###end title 31
###begin p 32
###xml 801 807 793 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000198-g006">Fig. 6</xref>
We analyzed different subpopulations of APC for their ability to cross-present epitopes from uBZLF1. Therefore monocyte-derived immature (iDC) and mature DC (mDC), as well as monocytes and B cells were generated from PBMC of HLA B8-positive individuals, pulsed with uBZLF1, washed extensively and co-cultured with autologous PBMC. Activation of T cells was assessed by IFN-gamma ELISpot. APC pulsed either with RAK or E10F peptides served as positive and negative controls. Dendritic cells pulsed with uBZLF1 showed a higher ability to restimulate antigen-specific T cells than monocytes and B cells. DC loaded with uBZLF1 were more efficient in the restimulation of IFN-gamma producing T cells than DC incubated with the RAK peptide, while the opposite effect was observed for monocytes and B cells (Fig. 6). These results indicate that various APC subpopulations may account for cross-presentation of uBZLF1 and subsequent reactivation of BZLF1-specific T cells in PBMC or whole blood cultures.
###end p 32
###begin title 33
iDC, mDC, monocytes and B cells are capable to process uBZLF1 for epitope-presentation to CTL.
###end title 33
###begin p 34
###xml 38 41 <span type="species:ncbi:10376">EBV</span>
iDC, mDC, monocytes, and B cells from EBV-seropositive, HLA B8-positive individuals were incubated for 2 h with 10 microg/ml uBZLF1, RAK or the E10F control peptide, washed and co-cultured with autologous PBMC at the indicated ratios. Numbers of positive cells were determined by ELISpot. The data show mean SFC values+s.d. of 5 replicate stimulations and are representative for 3 independent experiments with different donors.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Bogedain1">[24]</xref>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Adhikary1">[27]</xref>
###xml 754 758 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Precopio1">[28]</xref>
###xml 45 48 <span type="species:ncbi:10376">EBV</span>
In the present study we exemplified with the EBV immediate early protein BZLF1 a novel technology for the translocation of exogenous, soluble proteins into the HLA class I processing and presentation pathway of APC, which relies on the solubilisation of proteins with high molar urea and incubation of cells with these antigens in presence of low molar urea. In this study, we used BZLF1 as model antigen, because it includes an immunodominant HLA B8-restricted CTL epitope in addition to T helper cells epitopes [24],[27]. In addition, numbers of BZLF1-specific CTL are known to remain readily detectable over a long period of time, whereas specific T helper (Th) cell frequencies rapidly decline and persist at a low level following an acute infection [28].
###end p 36
###begin p 37
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 58 61 <span type="species:ncbi:10376">EBV</span>
In vitro stimulation of lymphocytes from HLA B8-positive, EBV-seropositive individuals with urea-solubilized BZLF1 revealed its strong capacity to restimulate BZLF1-specific CTL in addition to low numbers of IFN-gamma producing Th cells. In some of the tested individuals, uBZLF1 specifically reactivated higher numbers of CTL than the RAK peptide. This finding can be explained by the activation of CTL with specificity for additional CTL epitopes within BZLF1 (manuscript in preparation).
###end p 37
###begin p 38
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 46 49 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Similar to uBZLF1 urea-formulated recombinant CMV pp65 protein revealed an enhanced capacity to reactivate pp65-specific CD8+ T cells when compared to dialyzed, urea-free pp65 supporting the applicability of the urea-based strategy for proteins other than BZLF1.
###end p 38
###begin p 39
The transfer of uBZLF1 into the HLA class I processing and presentation pathway was shown to be mediated by urea as BZLF1 purified from urea by extensive dialysis lost its capacity to reactivate BZLF1-specific CTL.
###end p 39
###begin p 40
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Blake1">[29]</xref>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Blake2">[30]</xref>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 17 <span type="species:ncbi:10376">EBV</span>
###xml 122 125 <span type="species:ncbi:10376">EBV</span>
Unlike native EBV EBNA1 protein, which has been shown to enter the endogenous presentation pathway of dendritic cells and EBV lymphoblastoid cell lines (LCL) upon elongated exposure of 12 hours [29],[30], urea-free BZLF1 did not activate CD8+ T cells even after 20 hours of incubation. The molecular mechanisms underlying urea-mediated translocation of BZLF1 are still unclear. One possible explanation would be, that urea-denaturated proteins may translocate more efficiently than correctly folded proteins.
###end p 40
###begin p 41
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Nagahara1">[31]</xref>
###xml 232 235 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Dowdy and co-workers showed that complete denaturation in 8 M urea and subsequent removal of urea by ionic exchange chromatography or dialysis strongly enhances the translocation efficiency of some proteins linked to the PTD of the HIV Tat protein [31]. However, we showed that removal of urea from urea-denatured BZLF1 drastically abrogated its capacity to enter the endogenous processing pathway of APC.
###end p 41
###begin p 42
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Shi1">[32]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Shi2">[33]</xref>
Urea in the applied concentration revealed neither cytotoxic nor immune activating properties in cultured blood cells and immature dendritic cells, ruling out the possibility of unspecific activation of APC or T lymphocytes. Thus, effectiveness of urea formulation considerably differs from that of uric acid, which promotes the capacity of co-applied proteins to prime CTL responses by the stimulation of dendritic cell maturation [32],[33].
###end p 42
###begin p 43
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Console1">[34]</xref>
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Frankel1">[21]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Schwarze1">[35]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Pooga1">[36]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Frankel1">[21]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Joliot1">[37]</xref>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Wadia1">[38]</xref>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Kaplan1">[39]</xref>
###xml 295 298 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 315 338 <span type="species:ncbi:7227">Drosophila melanogaster</span>
BZLF1 contains a stretch of basic amino acid residues bearing resemblance to the PTD of Antp [34]. Several reports have demonstrated that PTD are able to transfer exogenous proteins across biological membranes into the cytosol of cells [21],[35],[36]. Initially discovered in the Tat protein of HIV [21] and in the Drosophila melanogaster Antp protein [37], these domains share clusters of basic amino acid residues, most commonly arginines, which mediate protein translocation into target cells. After binding of PTD to heparan sulfate on cell surfaces, APC internalize these proteins efficiently by macropinocytosis [38],[39]. Yet, deletion of this domain from BZLF1 had no significant influence on the urea-mediated transfer of BZLF1 into the HLA class I processing pathway, indicating that the arginine-rich domain of BZLF1 does not play a causal role in the cross-presentation of uBZLF1.
###end p 43
###begin p 44
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Delneste1">[40]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Jutras1">[41]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Daukas1">[42]</xref>
###xml 685 686 685 686 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 916 920 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Johannes1">[43]</xref>
Uptake of uBZLF1 into APC was proceeded by a temperature sensitive process, suggesting that the antigen is internalized by endocytosis, phagocytosis or macropinocytosis [40],[41] rather than direct penetration across the lipid bilayer. This assumption is further supported by the finding that cross-presentation of uBZLF1 is dose dependently abrogated in presence of sucrose, strongly suggesting that internalization of uBZLF1 occurs by clathrin-mediated endocytosis [42]. However, it is likely that uBZLF1 is rescued from endolysosomal degradation by release into the cytoplasm or to less acidic compartments, as cross-presentation of uBZLF1 is neither sensitive to chloroquine nor NH4Cl, two drugs known to prevent endosomal acidification. As an alternative pathway uBZLF1 might be transferred to the endoplasmic reticulum by retrograde transport pathways as previously described for the B fragment of shiga toxin [43]. The cellular transport pathway that facilitates the escape of uBZLF1 from destruction by lysosomal proteases remains unclear, since no well-defined mechanisms have been described for the transfer of endocytic structures to the cytosol.
###end p 44
###begin p 45
However, the impairment of uBZLF-induced CTL activation by epoxomicine and lactacystine, two inhibitors of proteasomal proteases clearly demonstrates the translocation of uBZLF1 to the cytosol and the essential role of the proteasome in the generation of uBZLF1-derived CTL epitopes.
###end p 45
###begin p 46
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Gromme1">[13]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Santambrogio1">[44]</xref>
The recognition of epitopes by CTL requires the interaction of a peptide-loaded HLA class I complex with specific T cell receptors. Our study shows that processed peptides are loaded onto new synthesized HLA class I molecules, as re-stimulation of BZLF1-specific CTL is completely abrogated in presence of BFA, a known inhibitor of protein secretion. Combined with our inhibition experiments of the proteasome this finding excludes the possibility of peptide loading on recycling HLA class I molecules in endolysosomal compartments [13]. Furthermore, these results rule out extracellular processing and loading of BZLF1 peptides on HLA molecules, as previously shown for HLA class II-restricted epitopes in immature dendritic cells [44].
###end p 46
###begin p 47
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Rodriguez1">[11]</xref>
###xml 79 82 79 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-KovacsovicsBankowski1">[4]</xref>
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Ackerman1">[45]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Shen1">[47]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Guermonprez1">[48]</xref>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Norbury1">[49]</xref>
Cross-presentation is a feature especially described for DC [11] and monocytes [4]. The ability of B cells to mediate cross-presentation is discussed controversial [45]-[47]. Our results showed that uBZLF1 is mainly cross-presented by iDC and mDC, while monocytes and B cells displayed reduced capacity to cross-present uBZLF1. The fact that both iDC and mDC are equally capable of cross-presenting uBZLF1 seems to be surprising, regarding their different capacity to capture antigens by phagocytosis and pinocytosis [48]. Yet, this finding supports our previous hypothesis of the cellular uptake of uBZLF1 by endocytosis, as this internalization route is not affected by the maturation state of DC [49].
###end p 47
###begin p 48
###xml 148 155 148 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Cresswell1">[50]</xref>
###xml 780 781 780 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Taken together, the data presented in this study reveal that the urea adjuvation technology constitutes a simple and useful tool for the concurrent ex vivo re-activation of antigen-specific CTL and Th cells. Compared to peptides the use of full length proteins provides the advantage of independence of HLA restriction. To circumvent this limitation large numbers of overlapping peptides would have to be synthesized. Another advantage of full length proteins is a natural processing of antigenic peptides and even spliced epitopes could be generated by this means [50]. Therefore this technology could improve the development of T cell diagnostics in a variety of viral, cancer and autoimmune diseases and may facilitate a novel strategy for the expansion of protein-specific CD8+ T cells for therapeutic applications.
###end p 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
Synthetic peptides and recombinant proteins
###end title 50
###begin p 51
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Bogedain1">[24]</xref>
###xml 203 209 203 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(BH10)</sub>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Wild1">[51]</xref>
###xml 79 82 <span type="species:ncbi:10376">EBV</span>
###xml 147 153 <span type="species:ncbi:10090">murine</span>
###xml 198 203 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 322 325 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The synthetic peptide RAK, representing a HLA B8-restricted CTL epitope within EBV BZLF1 (aa190-197) [24] and the control peptide E10F, covering a murine CTL epitope within the p24 capsid region of HIV-1(BH10) Gag (aa291-300) [51] were purchased from Synpep and reconstituted at 10 mg/ml in dimethylsulfoxide. Recombinant CMV pp65 protein was purchased from Miltenyi Biotec, Bergisch Gladbach, Germany.
###end p 51
###begin title 52
###xml 46 58 46 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
Expression and purification of BZLF1 and BZLF1Delta176-189
###end title 52
###begin p 53
###xml 201 213 201 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 319 331 315 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 384 396 376 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 398 405 386 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 466 478 454 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 518 521 496 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 70 73 <span type="species:ncbi:10376">EBV</span>
###xml 398 410 <span type="species:ncbi:511693">E. coli BL21</span>
The open reading frame encoding the cDNA (+1-735, 245 amino acids) of EBV BZLF1 was inserted into the pET5a plasmid (Novagen) using the EcoRI and BamHI sites. For generation of a plasmid encoding BZLF1Delta176-189, nucleotides 525-567 were removed by deletion PCR. The resulting plasmids were called pET5a-Z and pET5a-ZDelta176-189, respectively. For the production of BZLF1 and BZLF1Delta176-189, E. coli BL21-DE3/CP-RIL were transformed with the pET5c-Z or pET5a-ZDelta176-189 vectors, grown at 26degreesC to an O.D.600 of 0.8 and induced overnight with 1 mM IPTG. Full-length BZLF1 was expressed at 26degreesC for 20 h, truncated BZLF1 variant was expressed for 3 h at 37degreesC. Cells were harvested by centrifugation (10,000 g, 10 min) and stored at -80degreesC until further processing. Full-length BZLF1 was solubilized with urea from inclusion bodies, whereas truncated BZLF1 mutant was expressed in a soluble form and urea-denatured during purification process.
###end p 53
###begin p 54
###xml 126 138 126 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
Frozen cells were thawed and resuspended in buffer (BZLF1: 20 mM Bis-Tris propane (BTP), 5 mM EDTA, 100 mM NaCl, pH 7.0; BZLF1Delta176-189: 20 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, pH 7.5). Cells were lysed by two passages through the high pressure Basic-Z system (IUL Instruments) at 1,500 bar. To avoid DNA contamination crude extracts were incubated with 2 U/ml Benzonase (20 min, RT). Subsequently, cell lysates were cleared by centrifugation (30,000 g, 10 min, 4degreesC).
###end p 54
###begin p 55
For purification of full-length BZLF1, insoluble BZLF1 precipitate was washed (2 M urea, 20 mM BTP, 50 mM NaCl, pH 7.0) and then solubilized overnight in buffer containing 4 M urea (100 mM Tris, 4 M urea, 2 mM DTT, pH 7.5, overnight). After precipitation (30,000 g, 20 min), supernatant was further purified from contaminating proteins via acid precipitation. Therefore, pH was adjusted to 3.5 by addition of 1N HCl and further incubated for 30 min. Precipitated proteins were removed by centrifugation and BZLF1 containing supernatant was dialyzed (4 M urea, 20 mM citric acid, pH 3.5) and then loaded on a cation exchange column (Source S (GE Healthcare Life Sciences)). BZLF1 containing fractions eluted at approximately500 mM NaCl. BZLF1 containing fractions were pooled, dialyzed against (4 M urea, 20 mM Tris-HCl, 2 mM DTT, pH 7.5) and further purified by anion exchange chromatography (Source Q (GE Healthcare Life Sciences)). Pooled BZLF1 containing fraction (75-150 mM NaCl) was finally purified by gel filtration (Superdex 75 (GE Healthcare Life Sciences)).
###end p 55
###begin p 56
###xml 35 47 35 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 54 66 50 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 215 227 207 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 332 344 320 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 458 470 442 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 669 681 649 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
For purification of truncated BZLF1Delta176-189, BZLF1Delta176-189 was first precipitated by dialysis against 4 M urea, 20 mM formic acid, 50 mM NaCl, 1 mM EDTA, pH 4.0. After centrifugation (17,000 g, 15 min) BZLF1Delta176-189 was resolubilized by dialysis (6 M urea, 50 mM formic acid, 50 mM NaCl, pH 4.0). Soluble denatured BZLF1Delta176-189 containing fraction was loaded on a cation exchange column (Source Q (GE Healthcare Life Sciences)). Pooled BZLF1Delta176-189 fraction (300-600 mM NaCl) was neutralized (4 M urea, 20 mM Tris-HCl, 2 mM DTT, pH 7.5) and further purified by anion exchange chromatography (Source Q (GE Healthcare Life Sciences)). Finally, BZLF1Delta176-189 fraction (approximately100 mM NaCl) was purified by gel filtration (Superdex 75 (GE Healthcare Life Sciences)) chromatography for removal of further protein contamination from the expression host.
###end p 56
###begin p 57
###xml 47 59 47 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
###xml 101 113 97 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;176&#8211;189</sub>
Resulting full-length BZLF1 and truncated BZLF1Delta176-189 revealed a purity of >95%. BZLF1 or BZLF1Delta176-189 were adjusted to a final concentration of 1 mg/ml in 4 M urea with 2 mM DTE prior to use in stimulation experiments.
###end p 57
###begin title 58
Cell preparation
###end title 58
###begin p 59
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 935 939 935 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Hoves1">[52]</xref>
###xml 38 41 <span type="species:ncbi:10376">EBV</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
Whole blood was obtained from healthy EBV seropositive volunteers with known HLA compositions. The study was approved by the Institutional Ethics Committee. PBMC were prepared from heparinized blood by standard Ficoll-Paque (PAN) density centrifugation, washed twice in PBS, resuspended in RPMI-1640 medium containing 10% (vol/vol) human AB-serum and 1% (vol/vol) antibiotics (streptomycin 10 mg/ml; penicillin 10 mg/ml) and adjusted to 1x107 cells/ml. B cells and monocytes were purified from peripheral blood by MACS Sort magnetic beads through positive selection using anti-CD19 and anti-CD14 antibodies in MACS LS separation columns (Miltenyi Biotech) according to the manufacturer's protocol. Cell purity was assessed by flow cytometry using anti-CD20 (clone M5E2) and anti-CD14 (clone 2H7) (BD) antibodies. Production and phenotypical characterization of immature and mature dendritic cells was performed as previously described [52]. The purity of the APC populations was beyond 98%.
###end p 59
###begin title 60
Detection of IFN-gamma secreting T cells by ELISpot
###end title 60
###begin p 61
###xml 64 68 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000198-Bauer1">[53]</xref>
###xml 83 84 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
IFN-gamma ELISpot assays were performed as described previously [53]. Briefly, 2x105 PBMC were plated in 5 replicates into 96-well ELISpot plates (MAHA N45, Millipore) pre-coated with anti-IFN-gamma mAb 1D-1K (5 microg/ml) (MabTech) and stimulated overnight at 37degreesC. After removal of the cells, the plates were developed with the IFN-gamma specific biotinylated antibody 7-B6-1 (1 microg/ml) (MabTech) and streptavidine-alkaline phosphatase. Visualization of spots was performed with nitroblue tetrazolium substrate solution (Roche). IFN-gamma SFC were counted with a Bioreader 2000 (ByoSys).
###end p 61
###begin title 62
Flow cytometry analysis of intracellular cytokines
###end title 62
###begin p 63
###xml 981 982 954 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1034 1035 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
For intracellular cytokine staining, heparinized whole blood from healthy EBV positive donors was incubated for 7 h at 37degreesC, the last 4 h in presence of 10 microg/ml BFA (Sigma), with either 10 microg/ml of the indicated antigens or 0.04 M urea-buffer as control. Anti-CD49d and anti-CD28 monoclonal antibodies (BD) were added for co-stimulation according to the manufacturer's protocol. The following reagents were used for flow cytometric analysis, unless otherwise noted: fluorescein isothiocyanate (FITC)-conjugated anti-CD8 (clone B9.11), phycoerythrin-texas-red (ECD)-conjugated anti-CD3 (clone UCHT1), cychrometrade mark (Pc5)-labelled anti-CD4 (clone 13B8.2) and a phycoerythrin (PE)-conjugated anti-IFN-gamma antibody (clone 45.15) (all Beckman Coulter). Intracellular and surface markers were stained following fixation and permeabilisation of cells. Stained cells were run on a FACS Epics XL MCL flow cytometer (Beckman Coulter). Live-gating of lymphocytes and CD3+ events was performed during acquisition. Up to 2x106 events were acquired for each analysis. Results were reported as percentage of the gated population producing IFN-gamma.
###end p 63
###begin title 64
Antigen presentation assays and inhibitory compounds
###end title 64
###begin p 65
###xml 322 323 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Pure APC populations were pulsed with 10 microg/ml uBZLF1 or RAK peptide for 2 h at 37degreesC, washed twice and co-cultured with autologous PBMC for 20 h. For the analysis of the presentation pathway of uBZLF1, the following inhibitory compounds were used at indicated concentrations: sucrose, epoxomicin, lactacystin, NH4Cl, chloroquine (all from Sigma). The working concentration of BFA (Sigma) was 10 microg/ml. In antigen processing and presentation assays, PBMC or whole blood samples were pre-treated with the respective inhibitory compounds 45 min prior to pulsing with the indicated antigens. The compounds remained in the culture throughout the incubation. The number of IFN-gamma producing cells was assessed by ELISpot after stimulation of PBMC for 20 h or by FACS analysis following stimulation of whole blood for 7 h, respectively. Cell viability was analyzed by staining with propidium iodide (BD), according to the manufacturer's protocol.
###end p 65
###begin title 66
Statistical analysis
###end title 66
###begin p 67
Statstical analysis was evaluated using the Mann-Whitney U-test in SPSS for independent samples. A value of p<0.05 was considered significant.
###end p 67
###begin title 68
Accession numbers
###end title 68
###begin p 69
The accession number of the BZLF1 protein used in this study is YP_401673.
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin p 71
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 527 528 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 698 699 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 217 220 <span type="species:ncbi:10376">EBV</span>
Numbers and ratios of specifically reactivated CD8+ T cells and Th cells differ in uBZLF1, BZLF1 and RAK peptide stimulated blood cells of individual donors. Heparinized blood samples of four to six different HLA B8, EBV-seropositive donors were pulsed with 10 microg/ml uBZLF1, dialyzed BZLF1 or RAK peptide and the percentage of IFN-gamma positive Th cells and CD8+ T cells was assessed by flow cytometry. In these experiments we observed substantial differences in the total numbers and ratio of specifically reactivated CD8+ T cells upon stimulation with uBZLF1 and RAK. The removal of urea from uBZLF1 by extensive dialysis results in an almost complete loss of its capacity to restimulate CD8+ T cell (donor 1 to 4). Furthermore uBZLF1 stimulation of whole blood activated only limited (donor 1, 2) to undetectable (donors 3 to 6) numbers of Th cells for IFN-gamma production. NT: not tested.
###end p 71
###begin p 72
(0.64 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 233 234 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 494 495 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 498 499 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 506 507 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 510 511 492 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 263 266 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(u)pp65 (4 M urea) but not urea-free pp65 reactivates specific CD8+ T lymphocytes as determined by intracellular IFN-gamma staining. In contrast, removal of urea from upp65 had no effect on its ability to specifically restimulate CD4+ T cells. Whole blood from a CMV-seropositive donor was stimulated with either 10 microg/ml of pp65, upp65 or for control with 0.04 M urea. Cells were incubated for 7 h at 37 Cdegrees with 10 microg/ml BFA added for the last 4 h. Shown is the percentage of CD3+CD8+ or CD3+CD4+ cells expressing IFN-gamma from a representative stimulation of three independent experiments using different donors. Plots show log fluorescence intensity.
###end p 74
###begin p 75
(1.42 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 401 406 <span type="species:ncbi:9606">Human</span>
Urea does not induce secretion of cytokines from PBMC. PBMC were incubated with 0.04 M urea solution. Cells stimulated with medium alone, 100 ng/ml lipopolysaccharide (LPS) or 1 microg/ml phorbol 12-myristate 13-acetate (PMA)/Ionomycin served as negative and positive controls. After 24 h cell-free supernatants were collected and analyzed for depicted cytokines using a Luminex 100trade mark and the Human UltraSensitive Cytokine Ten-Plex Antibody Bead Kit. Values exceeding the detection limit are indicated by asterisks. The data represent mean values of two independent stimulations +s.d.
###end p 77
###begin p 78
(1.43 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 435 436 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Urea does not activate dendritc cells. iDC were generated by cultivation of monocytes in the presence of 500 microg/ml GM-CSF and IL-4 for 5 days. iDC were stimulated for 48 hours with 0.04 M urea solution and anayzed for the expression of costimulatory molecules and HLA-DR by flow cytometry. Cells stimulated with medium alone, 100 ng/ml LPS or Ionuleit cocktail (10 ng/ml IL-1beta, 10 ng/ml TNFalpha, 1000 U/ml IL-6, 1 microg/ml PGE2) served as negative and positive controls. The data shown are representative of 2 independent experiments with iDC of different donors.
###end p 80
###begin p 81
(2.02 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
The authors thank Christian Gerdes for technical assistance and Christian Schutz, Institute of Internal Medicine I, University Regensburg, for the assistance in the generation and culture of dendritic cells. We thank Dr. Christina Paulus and Dr. Michael Nevels for critical reading of the manuscript.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
###end article-title 85
###begin article-title 86
Proteolysis, proteasomes and antigen presentation.
###end article-title 86
###begin article-title 87
Cell biology of antigen processing in vitro and in vivo.
###end article-title 87
###begin article-title 88
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.
###end article-title 88
###begin article-title 89
###xml 47 52 <span type="species:ncbi:9606">human</span>
Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells.
###end article-title 89
###begin article-title 90
Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.
###end article-title 90
###begin article-title 91
CpG-DNA aided cross-priming by cross-presenting B cells.
###end article-title 91
###begin article-title 92
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance.
###end article-title 92
###begin article-title 93
Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens.
###end article-title 93
###begin article-title 94
A new foreign policy: MHC class I molecules monitor the outside world.
###end article-title 94
###begin article-title 95
Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.
###end article-title 95
###begin article-title 96
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.
###end article-title 96
###begin article-title 97
Recycling MHC class I molecules and endosomal peptide loading.
###end article-title 97
###begin article-title 98
###xml 96 110 <span type="species:ncbi:10798">parvovirus B19</span>
CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
###end article-title 98
###begin article-title 99
Genetically modified dendritic cells for cancer immunotherapy.
###end article-title 99
###begin article-title 100
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.
###end article-title 100
###begin article-title 101
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
###end article-title 101
###begin article-title 102
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
###end article-title 102
###begin article-title 103
###xml 90 103 <span type="species:ncbi:11234">measles virus</span>
In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein.
###end article-title 103
###begin article-title 104
Structure and function: heat shock proteins and adaptive immunity.
###end article-title 104
###begin article-title 105
###xml 40 68 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Cellular uptake of the tat protein from human immunodeficiency virus.
###end article-title 105
###begin article-title 106
Dendritic cells: specialized and regulated antigen processing machines.
###end article-title 106
###begin article-title 107
Activation of lysosomal function during dendritic cell maturation.
###end article-title 107
###begin article-title 108
###xml 85 103 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.
###end article-title 108
###begin article-title 109
Endogenous MHC class II processing of a viral nuclear antigen after autophagy.
###end article-title 109
###begin article-title 110
###xml 60 65 <span type="species:ncbi:9606">human</span>
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
###end article-title 110
###begin article-title 111
###xml 11 29 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
###end article-title 111
###begin article-title 112
###xml 41 44 <span type="species:ncbi:10376">EBV</span>
Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection.
###end article-title 112
###begin article-title 113
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
###end article-title 113
###begin article-title 114
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 96 99 <span type="species:ncbi:10376">EBV</span>
The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
###end article-title 114
###begin article-title 115
Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.
###end article-title 115
###begin article-title 116
Molecular identification of a danger signal that alerts the immune system to dying cells.
###end article-title 116
###begin article-title 117
Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model.
###end article-title 117
###begin article-title 118
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans.
###end article-title 118
###begin article-title 119
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
In vivo protein transduction: delivery of a biologically active protein into the mouse.
###end article-title 119
###begin article-title 120
Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo.
###end article-title 120
###begin article-title 121
Antennapedia homeobox peptide regulates neural morphogenesis.
###end article-title 121
###begin article-title 122
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.
###end article-title 122
###begin article-title 123
Cationic TAT peptide transduction domain enters cells by macropinocytosis.
###end article-title 123
###begin article-title 124
Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.
###end article-title 124
###begin article-title 125
Phagocytosis: at the crossroads of innate and adaptive immunity.
###end article-title 125
###begin article-title 126
Inhibition of receptor-mediated but not fluid-phase endocytosis in polymorphonuclear leukocytes.
###end article-title 126
###begin article-title 127
Retrograde transport of KDEL-bearing B-fragment of Shiga toxin.
###end article-title 127
###begin article-title 128
Extracellular antigen processing and presentation by immature dendritic cells.
###end article-title 128
###begin article-title 129
Cellular mechanisms governing cross-presentation of exogenous antigens.
###end article-title 129
###begin article-title 130
B lymphocytes participate in cross-presentation of antigen following gene gun vaccination.
###end article-title 130
###begin article-title 131
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.
###end article-title 131
###begin article-title 132
Antigen presentation and T cell stimulation by dendritic cells.
###end article-title 132
###begin article-title 133
Drinking a lot is good for dendritic cells.
###end article-title 133
###begin article-title 134
Cell biology. Cutting and pasting antigenic peptides.
###end article-title 134
###begin article-title 135
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
###end article-title 135
###begin article-title 136
###xml 54 59 <span type="species:ncbi:9606">human</span>
Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
###end article-title 136
###begin article-title 137
Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells.
###end article-title 137
###begin p 138
The authors have declared that no competing interests exist.
###end p 138
###begin p 139
This study was supported by the Reform C grants 3010008 and 3010011 from the clinical centre of the University of Regensburg and by the German Research Foundation (DFG), grant Mo620/7-1. The sponsors did not influence the generation or interpretation of the data.
###end p 139

